

Josh Levitsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1210150/publications.pdf>

Version: 2024-02-01

170
papers

7,358
citations

53794

45
h-index

64796

79
g-index

188
all docs

188
docs citations

188
times ranked

7234
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. American Journal of Transplantation, 2016, 16, 2816-2835.	4.7	451
2	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine, 2014, 371, 2375-2382.	27.0	377
3	Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Annals of Internal Medicine, 2005, 143, 870.	3.9	344
4	The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. American Journal of Transplantation, 2017, 17, 2790-2802.	4.7	281
5	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016, 64, 717-735.	3.7	243
6	Herpes simplex virus hepatitis: An analysis of the published literature and institutional cases. Liver Transplantation, 2007, 13, 1428-1434.	2.4	229
7	Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging. American Journal of Roentgenology, 2011, 196, 553-561.	2.2	198
8	Solid Organ Transplantation From Hepatitis B Virus-Positive Donors: Consensus Guidelines for Recipient Management. American Journal of Transplantation, 2015, 15, 1162-1172.	4.7	196
9	Age and liver transplantation. Journal of Hepatology, 2019, 70, 745-758.	3.7	186
10	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 2018, 102, 727-743.	1.0	178
11	Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2017, 15, 584-593.e2.	4.4	162
12	High early cardiovascular mortality after liver transplantation. Liver Transplantation, 2014, 20, 1306-1316.	2.4	154
13	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-ARGET study. Hepatology, 2017, 66, 1090-1101.	7.3	149
14	Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. American Journal of Transplantation, 2016, 16, 2684-2694.	4.7	130
15	Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon. Gastroenterology, 2012, 142, 1132-1139.e1.	1.3	104
16	Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. American Journal of Transplantation, 2019, 19, 1397-1409.	4.7	103
17	Overview of immunosuppression in liver transplantation. World Journal of Gastroenterology, 2009, 15, 4225.	3.3	102
18	Diagnosis and Therapy of Alcoholic Liver Disease. Seminars in Liver Disease, 2004, 24, 233-247.	3.6	101

#	ARTICLE	IF	CITATIONS
19	Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. <i>Journal of Hepatology</i> , 2020, 72, 481-488.	3.7	93
20	A Survey of CMV Prevention Strategies After Liver Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 158-161.	4.7	86
21	Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. <i>Liver Transplantation</i> , 2008, 14, 1498-1504.	2.4	83
22	A point-of-care based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score. <i>Hepatology</i> , 2017, 66, 1968-1979.	7.3	82
23	A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1-8.	1.3	78
24	Perioperative Ledipasvir/Sofosbuvir for HCV in Liver-Transplant Recipients. <i>New England Journal of Medicine</i> , 2016, 375, 2106-2108.	27.0	77
25	Operative Risk of Total Hip and Knee Arthroplasty in Cirrhotic Patients. <i>Journal of Arthroplasty</i> , 2005, 20, 460-466.	3.1	76
26	Posttransplant Hyperglycemia is Associated With Increased Risk of Liver Allograft Rejection. <i>Transplantation</i> , 2010, 89, 222-226.	1.0	76
27	Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. <i>Liver Transplantation</i> , 2015, 21, 22-28.	2.4	74
28	Fulminant Liver Failure Associated with the Use of Black Cohosh. <i>Digestive Diseases and Sciences</i> , 2005, 50, 538-539.	2.3	73
29	Operational tolerance: Past lessons and future prospects. <i>Liver Transplantation</i> , 2011, 17, 222-232.	2.4	72
30	Sodium Ion/Hydrogen Ion Exchange Inhibition: A New Pharmacologic Approach to Myocardial Ischemia and Reperfusion Injury. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 887-897.	2.0	69
31	Tolerance in clinical liver transplantation. <i>Human Immunology</i> , 2018, 79, 283-287.	2.4	69
32	The Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells. <i>Science</i> , 2022, 375, 411-418.	12.6	64
33	A comprehensive pipeline for translational top-down proteomics from a single blood draw. <i>Nature Protocols</i> , 2019, 14, 119-152.	12.0	62
34	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1376-1385.	6.1	60
35	Phosphatidylethanol Detects Moderate-to-Heavy Alcohol Use in Liver Transplant Recipients. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 857-862.	2.4	60
36	Magnetic Resonance Elastography and Biomarkers to Assess Fibrosis From Recurrent Hepatitis C in Liver Transplant Recipients. <i>Transplantation</i> , 2011, 92, 581-586.	1.0	57

#	ARTICLE	IF	CITATIONS
37	National survey of provider opinions on controversial characteristics of liver transplant candidates. <i>Liver Transplantation</i> , 2013, 19, 395-403.	2.4	57
38	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55
39	The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 733-736.	2.4	52
40	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. <i>Hepatology</i> , 2013, 57, 239-248.	7.3	52
41	Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. <i>Hepatology</i> , 2019, 69, 1273-1286.	7.3	52
42	Association of hepatic artery stenosis and biliary strictures in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 849-854.	2.4	51
43	Varicella Infection Following Varicella Vaccination in a Liver Transplant Recipient. <i>American Journal of Transplantation</i> , 2002, 2, 880-882.	4.7	50
44	Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. <i>Hepatology</i> , 2014, 60, 2017-2026.	7.3	50
45	A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction[Link]. <i>Hepatology</i> , 2019, 69, 1219-1230.	7.3	47
46	Acid-Base and Potassium Disorders in Liver Disease. <i>Seminars in Nephrology</i> , 2006, 26, 466-470.	1.6	46
47	Kidney Failure Associates With T Cell Exhaustion and Imbalanced Follicular Helper T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 583702.	4.8	46
48	National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 213-223.	2.4	45
49	Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. <i>Hepatology</i> , 2020, 72, 569-583.	7.3	45
50	The impact of coronary artery disease on outcomes after liver transplantation. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 875-885.	1.5	42
51	Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. <i>The Lancet Digital Health</i> , 2021, 3, e295-e305.	12.3	41
52	MELD+GRAIL+Na: Glomerular Filtration Rate and Mortality on Liver Transplant Waiting List. <i>Hepatology</i> , 2020, 71, 1766-1774.	7.3	40
53	The safety and outcome of joint replacement surgery in liver transplant recipients. <i>Liver Transplantation</i> , 2003, 9, 373-376.	2.4	37
54	Glycemic Control by A Glucose Management Service and Infection Rates After Liver Transplantation. <i>Endocrine Practice</i> , 2011, 17, 546-551.	2.1	37

#	ARTICLE	IF	CITATIONS
55	Inhibitory Effects of Belatacept on Allospecific Regulatory T-Cell Generation in Humans. Transplantation, 2013, 96, 689-696.	1.0	37
56	Proteoforms in Peripheral Blood Mononuclear Cells as Novel Rejection Biomarkers in Liver Transplant Recipients. American Journal of Transplantation, 2017, 17, 2458-2467.	4.7	37
57	The Human "Treg MLR" Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	1.0	36
58	Herpes zoster infection after liver transplantation: A case-control study. Liver Transplantation, 2005, 11, 320-325.	2.4	35
59	Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. Journal of Hepatology, 2009, 51, 874-880.	3.7	34
60	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation, 2011, 91, 199-206.	1.0	34
61	Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transplantation, 2011, 17, 32-37.	2.4	34
62	Infection and Alcoholic Liver Disease. Clinics in Liver Disease, 2016, 20, 595-606.	2.1	33
63	Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. Journal of Hepatology, 2017, 67, 517-525.	3.7	31
64	Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. American Journal of Transplantation, 2022, 22, 532-540.	4.7	31
65	Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. American Journal of Transplantation, 2020, 20, 2173-2183.	4.7	30
66	Hepatic complications of hematopoietic cell transplantation. Current Gastroenterology Reports, 2007, 9, 60-65.	2.5	29
67	Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Human Immunology, 2009, 70, 146-150.	2.4	29
68	Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. American Journal of Transplantation, 2018, 18, 2506-2512.	4.7	29
69	The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology, 2020, 72, 1127-1138.	7.3	29
70	Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. American Journal of Transplantation, 2020, 20, 797-807.	4.7	28
71	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	4.7	28
72	A meta-analysis of complications following deceased donor liver transplant. American Journal of Surgery, 2014, 208, 605-618.	1.8	27

#	ARTICLE	IF	CITATIONS
73	Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. <i>Hepatology</i> , 2022, 76, 1862-1879.	7.3	27
74	Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1096-1107.	1.0	26
75	Patients With Persistently Low MELD-Na Scores Continue to Be at Risk of Liver-related Death. <i>Transplantation</i> , 2020, 104, 1413-1418.	1.0	26
76	The prevalence, risk factors, and outcomes of medication trade-offs in kidney and liver transplant recipients: a pilot study. <i>Transplant International</i> , 2018, 31, 870-879.	1.6	25
77	Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. <i>Clinical Transplantation</i> , 2008, 22, 222-228.	1.6	24
78	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-3279.	3.6	24
79	Use of Six-Minute Walk Test to Measure Functional Capacity After Liver Transplantation. <i>Physical Therapy</i> , 2016, 96, 1456-1467.	2.4	23
80	The utility of pulmonary function testing in predicting outcomes following liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 805-811.	2.4	23
81	Crohn's Disease and Takayasu's Arteritis. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 454-456.	2.2	22
82	Chicken pox after pediatric liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 1563-1566.	2.4	22
83	In-Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of Coronavirus Disease 2019, and Areas of Opportunity. <i>Liver Transplantation</i> , 2020, 26, 1354-1358.	2.4	22
84	Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. <i>Liver Transplantation</i> , 2014, 20, 1034-1044.	2.4	20
85	Simulation Modeling of the Impact of Proposed New Simultaneous Liver and Kidney Transplantation Policies. <i>Transplantation</i> , 2015, 99, 424-430.	1.0	20
86	Incidence and impact of rejection following simultaneous liver-kidney transplantation. <i>Journal of Hepatology</i> , 2015, 62, 340-345.	3.7	20
87	Transjugular Intrahepatic Portosystemic Shunt with Thrombectomy for the Treatment of Portal Vein Thrombosis After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 529-534.	2.3	19
88	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. <i>Human Immunology</i> , 2012, 73, 141-149.	2.4	19
89	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651.	1.0	19
90	A Comprehensive Review of Outcome Predictors in Low MELD Patients. <i>Transplantation</i> , 2020, 104, 242-250.	1.0	19

#	ARTICLE	IF	CITATIONS
91	Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study. <i>Hepatology</i> , 2021, 74, 926-936.	7.3	19
92	MRI-guided Biopsy to Correlate Tissue Specimens with MR Elastography Stiffness Readings in Liver Transplants. <i>Academic Radiology</i> , 2012, 19, 1121-1126.	2.5	18
93	Comprehensive Review on Colorectal Cancer and Transplant. <i>American Journal of Transplantation</i> , 2017, 17, 2761-2774.	4.7	18
94	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	3.3	18
95	Donor-derived Viral Infections in Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1824-1836.	1.0	17
96	External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of Renal Recovery After Liver Transplantation. <i>Hepatology</i> , 2019, 70, 1349-1359.	7.3	17
97	Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors. <i>Clinical Transplantation</i> , 2009, 23, 943-950.	1.6	16
98	Next level of immunosuppression: Drug/immune monitoring. <i>Liver Transplantation</i> , 2011, 17, S60-S65.	2.4	16
99	Does the Liver Provide Immunosuppressive Advantage?. <i>Clinical Liver Disease</i> , 2019, 13, 180-183.	2.1	16
100	Liver-related mortality is similar among men and women with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1072-1081.	3.7	16
101	Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. <i>Transplantation</i> , 2017, 101, 1056-1066.	1.0	15
102	Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 257-263.	1.6	15
103	Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation. <i>Hepatology</i> , 2020, 71, 1775-1786.	7.3	15
104	Ethical Considerations of Transplantation and Living Donation for Patients with Alcoholic Liver Diseases. <i>AMA Journal of Ethics</i> , 2016, 18, 163-173.	0.7	15
105	Biomarkers of rejection in liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 154-158.	1.6	13
106	Keeping high model for end-stage liver disease score liver transplantation candidates alive. <i>Liver Transplantation</i> , 2015, 21, 1428-1437.	2.4	12
107	Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Transplantation Direct</i> , 2017, 3, e188.	1.6	12
108	Donor-Specific Antibodies in Liver Transplantation. <i>Clinical Liver Disease</i> , 2020, 15, 13-16.	2.1	12

#	ARTICLE	IF	CITATIONS
109	Paediatric to adult liver transition services: the state of play in the UK. <i>Clinical Medicine</i> , 2019, 19, 425-426.	1.9	12
110	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.8	12
111	The renal benefit of mycophenolate mofetil after liver transplantation. <i>Clinical Transplantation</i> , 2011, 25, E88-E95.	1.6	11
112	Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. <i>PLoS ONE</i> , 2016, 11, e0156535.	2.5	11
113	Prediction of Liver Transplant Rejection With a Biologically Relevant Gene Expression Signature. <i>Transplantation</i> , 2022, 106, 1004-1011.	1.0	11
114	Oral Vitamin A Therapy for a Patient With a Severely Symptomatic Postradiation Anal Ulceration. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 679-682.	1.3	9
115	Follow-up of the Post-Liver Transplantation Patient. <i>Clinics in Liver Disease</i> , 2017, 21, 793-813.	2.1	9
116	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-ARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	4.3	9
117	Living Donor Liver Transplantation When Deceased Donor Is Not Possible or Timely: Case Examples and Ethical Perspectives. <i>Liver Transplantation</i> , 2020, 26, 431-436.	2.4	9
118	Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 572-572.	2.4	9
119	Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation. <i>Blood</i> , 2011, 118, 3448-3449.	1.4	8
120	Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients. <i>Clinics in Liver Disease</i> , 2013, 17, 737-747.	2.1	8
121	Immunosuppression withdrawal following liver transplantation: The older, the wiser – but maybe too late. <i>Hepatology</i> , 2013, 58, 1529-1532.	7.3	8
122	The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment. <i>Current Infectious Disease Reports</i> , 2014, 16, 413.	3.0	8
123	Erythropoietin administration expands regulatory T cells in patients with autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2021, 119, 102629.	6.5	8
124	Mycophenolate mofetil monotherapy in liver transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, E639-E646.	1.6	7
125	Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin. <i>Human Immunology</i> , 2016, 77, 367-374.	2.4	7
126	The liver transplant recipient: what you need to know for long-term care. <i>Journal of Family Practice</i> , 2006, 55, 136-44.	0.2	7

#	ARTICLE	IF	CITATIONS
127	Chronic rejection related to hepatitis B immunoglobulin discontinuation in a liver transplant recipient. <i>Transplant International</i> , 2011, 24, e104-e106.	1.6	6
128	Inpatient Hypoglycemic Events in a Comparative Effectiveness Trial for Glycemic Control in a High-Risk Population. <i>Endocrine Practice</i> , 2016, 22, 1040-1047.	2.1	6
129	Probiotics: Application of "healthy" bacteria to liver transplant recipients. <i>Hepatology</i> , 2006, 44, 507-510.	7.3	5
130	Constrictive Pericarditis as a Cause of Refractory Ascites. <i>ACG Case Reports Journal</i> , 2015, 2, 175-177.	0.4	5
131	Immunosuppressive Drug Levels in Liver Transplant Recipients: Impact in Decision Making. <i>Seminars in Liver Disease</i> , 2019, 39, 414-421.	3.6	5
132	Comanagement With Nephrologist Care Is Associated With Fewer Cardiovascular Events Among Liver Transplant Recipients With Chronic Kidney Disease. <i>Transplantation Direct</i> , 2021, 7, e766.	1.6	5
133	Donor quality of life after living donor liver transplantation: a review of the literature. <i>Digestive Medicine Research</i> , 2021, 4, 49-49.	0.2	5
134	Not everything that counts can be counted: Tracking long-term outcomes in pediatric liver transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1182-1190.	4.7	5
135	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. <i>Human Immunology</i> , 2021, 82, 81-88.	2.4	4
136	Poor Practitioner Adherence to Clinical Tobacco Use Guidelines in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1288.	1.6	4
137	Donor and recipient effects on graft and patient survival. <i>Clinical Liver Disease</i> , 2013, 2, 152-155.	2.1	3
138	Medication nonadherence in liver transplantation. <i>Clinical Liver Disease</i> , 2017, 10, 157-160.	2.1	3
139	Advances in Rejection Management. <i>Clinics in Liver Disease</i> , 2021, 25, 53-72.	2.1	3
140	Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	3
141	Ethical Issues When Considering Liver Donor Versus Deceased Donor Liver Transplantation. <i>Clinical Liver Disease</i> , 2021, 17, 71-74.	2.1	3
142	Profiling the liver graft. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 17-22.	1.6	3
143	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allospecific CTL by Human CD4+CD127 ^{hi} CD25+FOXP3+ Cells Generated in MLR. <i>PLoS ONE</i> , 2011, 6, e22450.	2.5	3
144	Frailty after liver transplantation: The strong survive but may not prosper. <i>American Journal of Transplantation</i> , 2018, 18, 1841-1842.	4.7	2

#	ARTICLE	IF	CITATIONS
145	Transplanting livers from HCV infected donors into HCV negative recipients: Promise but mind the pitfalls. American Journal of Transplantation, 2019, 19, 1264-1265.	4.7	2
146	Harnessing T cell exhaustion to improve solid organ transplant outcomes. American Journal of Transplantation, 2021, 21, 1660-1661.	4.7	2
147	Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Experimental and Clinical Transplantation, 2018, 16, 182-190.	0.5	2
148	The answer at our fingertips: Volume status in cirrhosis determined by machine learning and pulse oximeter waveform. Physiological Reports, 2022, 10, e15223.	1.7	2
149	Too Much or Not Enough? Induction Immunosuppression in the Simultaneous Liver-Kidney Recipient. Liver Transplantation, 2019, 25, 365-366.	2.4	1
150	Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1778-1780.	6.1	1
151	Mission accomplished? Early data from the simultaneous liver-kidney transplantation allocation policy. American Journal of Transplantation, 2021, 21, 3513-3515.	4.7	1
152	When evidence is lacking: a mixed-methods approach for the development of practice guidance in liver transplantation. Gastroenterology Report, 2021, 9, 22-30.	1.3	1
153	THE CONTINUED IMPACT OF ACUTE REJECTION IN THE LAST DECADE OF LIVER TRANSPLANTATION. , 2022, , .		1
154	The natural history and outcome of large bowel dysplasia and cancer in patients with Crohn's colitis. Gastroenterology, 2003, 124, A211.	1.3	0
155	Oral vitamin A for the treatment of chronic radiation proctopathy: A randomized, controlled trial. Gastroenterology, 2003, 124, A64.	1.3	0
156	40-OR. Human Immunology, 2012, 73, 33.	2.4	0
157	To kidney or not to kidney, when is the question. Liver Transplantation, 2012, 18, 875-877.	2.4	0
158	Find it in your heart. Liver Transplantation, 2013, 19, 567-568.	2.4	0
159	Reply. Liver Transplantation, 2014, 20, 499-499.	2.4	0
160	OR26. Human Immunology, 2014, 75, 21.	2.4	0
161	New models to enhance the assessment of mortality risk in low model for end-stage liver disease patients: "Objectifying" the subjective. Liver Transplantation, 2014, 20, 1153-1154.	2.4	0
162	Mechanisms and Strategies for Tolerance in Liver Transplantation. Current Transplantation Reports, 2016, 3, 325-333.	2.0	0

#	ARTICLE	IF	CITATIONS
163	Liver Websites. Transplantation, 2016, 100, 1594.	1.0	0
164	Reply. Hepatology, 2017, 66, 2089-2090.	7.3	0
165	Prevention and Management of HBV in Organ Transplantation. Current Hepatology Reports, 2020, 19, 266-275.	0.9	0
166	Reply. Liver Transplantation, 2020, 26, 1068-1068.	2.4	0
167	Interest in Immunosuppression Withdrawal among Liver Transplant and Autoimmune Hepatitis Patients. Gastroenterology Insights, 2021, 12, 147-154.	1.2	0
168	An Unusual Cause of Acute Pancreatitis in a Liver Transplant Recipient. Transplantation Direct, 2021, 7, e694.	1.6	0
169	Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. Seminars in Liver Disease, 2021, 41, 308-320.	3.6	0
170	CAQ Corner: Basic concepts of transplant immunology. Liver Transplantation, 2023, 29, 331-339.	2.4	0